if you see the updated slide below, two points worth noting:
1) VP-002 is now PYC-001; which seems to indicate DR is now no longer a program/asset, and has been replaced with ADOA being the defined co-lead
2) 100% ownership for ADOA and all future Vision Pharma pipeline assets; may be a result of Lion Eye not taking up the last funding round?
For the pipeline CNS is still in the pipeline; but will likely remain undisclosed until IP is locked in
This aligns with Rohan’s presentation that 3 assets will be delivered this year, with a potential 4th as backup being worked up.
(20min delay)